Medical Research
Study Links Traumatic Brain Injuries to Increased Brain Cancer Risk in Veterans
A recent study published in JAMA Network reveals that military veterans with traumatic brain injuries face a significantly higher risk of developing brain cancer, highlighting the urgent need for advanced treatments and preventive measures.
Fifty 1 Labs and UAV Corp Complete Historic REVIVE Trial, Pioneering Long COVID Treatment
Fifty 1 Labs, Inc. and UAV Corp have successfully completed the REVIVE Adaptive Platform Trial, marking a significant advancement in the treatment of Long COVID and positioning the companies for growth in the functional medicine market.
CNS Pharmaceuticals Inc. Showcases Lead Cancer Treatment Program in Virtual CEO Segment
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) emphasizes its lead cancer treatment program during a virtual CEO segment, highlighting potential advancements in brain and central nervous system cancer therapies.
University of Sydney Researchers Discover Potential Breakthrough in Parkinson's Treatment
A preclinical study by University of Sydney researchers has successfully reversed Parkinson's-like symptoms in mice by targeting a malfunctioning protein, offering hope for future human treatments.
Quantum BioPharma Submits MS Drug Candidate to UK's ILAP Program
Quantum BioPharma Ltd. advances its multiple sclerosis treatment, Lucid-MS, through the UK's Innovative Licensing and Access Pathway, aiming to accelerate patient access to this innovative therapy.
NeuroEyeCoach Study Highlights Benefits for Vision Rehabilitation in Home and Clinic Settings
A new study on NovaVision's NeuroEyeCoach demonstrates significant improvements in visual search performance for patients, whether used at home or in a clinic, supporting its role in vision rehabilitation.
Benova Mouth Rinse Study Shows Significant Reduction in Inflammatory Marker TNF-Alpha
A recent study presented at the 2025 Diabetic Limb Salvage Conference reveals the Benova Mouth Rinse System's ability to reduce TNF-alpha, a key inflammatory marker, by 17% within two minutes, offering potential relief for millions suffering from oral inflammatory conditions.
Clene Inc. Advances Neurofilament Biomarker Analysis for CNM-Au8 in ALS with FDA Support
Clene Inc. is set to conduct a neurofilament biomarker analysis for CNM-Au8 in ALS patients, following constructive FDA feedback, aiming to support an accelerated approval submission in 2025.
Oragenics Inc. Raises $16.5 Million to Advance Intranasal Concussion Therapy
Oragenics Inc. has successfully closed a $16.5 million public offering to fund the development of its intranasal therapy for concussions, marking a significant step forward in neurological disorder treatments.
Soligenix Inc. Reports Promising Phase 3 Progress for HyBryte(TM) in CTCL Treatment
Soligenix Inc. shares encouraging interim results from its phase 3 trial of HyBryte(TM) for cutaneous T-cell lymphoma, highlighting potential advancements in treatment options for this rare disease.
GeoVax Announces $6 Million Public Offering to Advance Immunotherapies and Vaccines
GeoVax Labs, Inc. secures approximately $6 million in a public offering to fund the development of its immunotherapies and vaccines against cancer and infectious diseases.
Cardiovascular Disease Risk Factors on the Rise Despite Medical Advances
The American Heart Association's 2025 report highlights increasing risk factors for cardiovascular diseases, signaling a pressing public health challenge.
SeaStar's QUELIMMUNE Shows Promise in Halving Pediatric Sepsis Mortality Rates
SeaStar Medical's QUELIMMUNE therapy, approved by the FDA in 2024, has demonstrated the potential to reduce pediatric sepsis mortality rates by half, offering hope for critically ill children with acute kidney injury.
Scinai Immunotherapeutics Ltd. Highlights PC111 Breakthrough Following Top Italian Dermatology Award
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) celebrates Dr. Roberta Lotti's award-winning research on PC111, a promising treatment for pemphigus vulgaris, underscoring its potential as a non-immunosuppressive therapy for autoimmune skin conditions.
BiomX Inc.: A Biotech Pioneer with Pentagon Backing and Promising Phage Therapy
BiomX Inc. (NYSE: PHGE), a biotech company with a market cap of $13 million, has secured $40 million in non-dilutive funding from the U.S. Defense Health Agency, highlighting its potential in addressing antibiotic-resistant infections with phage therapy.
New Scanning Method Research Funded to Improve Brain Tumor Treatment
Researchers from NHS Grampian and the University of Aberdeen receive funding to explore a novel scanning method that could enhance the treatment of aggressive brain tumors, specifically glioblastomas.
Shift in Heart Disease Deaths Highlights Advances and Emerging Challenges
Over the past 50 years, heart disease death rates have significantly decreased, with a shift from heart attacks to heart failure, arrhythmias, and hypertensive heart disease, reflecting medical advancements and emerging health challenges.
CNS Pharmaceuticals Inc. Sheds Light on GBM Treatment Advances in KOL Segment
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) explores the potential of its lead product candidate, TPI 287, in treating Glioblastoma Multiforme (GBM) and future metastatic tumor indications, as discussed by Dr. Erin Dunbar in a recent Virtual Investor KOL Connect segment.
Axim Biotechnologies Seeks FDA CLIA Waiver for Lactoferrin Diagnostic Test
Axim Biotechnologies has taken a significant step towards broadening access to its Lactoferrin diagnostic test by filing a Pre-Submission with the FDA for a CLIA Waiver, aiming to facilitate easier diagnosis and monitoring of Aqueous Deficient Dry Eye Disease.
Study Shows Multiple Doses of Extracellular Vesicles Could Reduce Lung Injury Risk in ICU Patients
A new study by Leksum LLC suggests that multiple doses of extracellular vesicles may significantly improve diaphragm muscle function in mechanically ventilated ICU patients, potentially reducing the risk of lung injury and improving recovery outcomes.
Research Reveals Why Most Smokers Avoid Lung Cancer Despite Tobacco Use
A new study explains the biological mechanisms that protect most smokers from developing lung cancer, offering insights into prevention and treatment strategies.
Scientific Breakthrough in Anti-Aging: Key Ingredients Show Promise
Recent dermatological research highlights five key ingredients—Matrixyl, Argireline, Volufiline, Retinol, and PDRN—that offer significant anti-aging benefits, addressing wrinkles, skin volume loss, and cellular senescence with minimal irritation.
Soligenix's SGX302 Shows Promise in Psoriasis Treatment
Soligenix Inc.'s SGX302, a novel therapy for psoriasis, has demonstrated effectiveness and safety in Phase 2a trials, offering hope to millions affected by this autoimmune disorder.
Cure Alzheimer’s Fund Honors Breakthrough Research with Jeffrey L. Morby Prize
The Cure Alzheimer’s Fund has awarded the Jeffrey L. Morby Prize to researchers Andrew S. Yoo and Zhao Sun for their innovative study on modeling late-onset Alzheimer’s disease, marking a significant step forward in understanding and potentially treating the condition.
Study Reveals Unchanged Prevalence of Psoriasis in the U.S., Highlights Need for Better Treatments
A recent study published in the Journal of American Academy of Dermatology shows the prevalence of psoriasis among U.S. adults remains steady at 3% over the last decade, underscoring the ongoing need for effective treatments and improved diagnostic access.
Soligenix Advances Treatment for Behçet’s Disease with New Clinical Trial
Soligenix Inc. has initiated a clinical trial for SGX945, a potential treatment for Behçet’s disease, a rare autoimmune disorder with limited treatment options, highlighting a significant step towards addressing the unmet needs of patients globally.
Quantum BioPharma Advances MS Research with Groundbreaking PET Imaging Study
Quantum BioPharma Ltd. has initiated a pioneering PET imaging study with Massachusetts General Hospital to track myelin integrity in multiple sclerosis patients, potentially revolutionizing treatment evaluation.
BiomX Inc. Achieves Breakthrough in Treating Antibiotic-Resistant Infections
BiomX Inc. has reported successful Phase 2 clinical trial results for treating diabetic foot bone infections and cystic fibrosis with bacteriophage therapy, offering a potential solution to the growing antibiotic resistance crisis.
Lantern Pharma Inc. Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial
Lantern Pharma Inc. (NASDAQ: LTRN) has reported a significant clinical outcome in its Phase 2 HARMONIC(TM) trial, showcasing the potential of its LP-300 treatment in combination with standard chemotherapy for never-smoker patients with advanced non-small cell lung cancer (NSCLC), marking a pivotal moment in oncology treatment.
Tonix Pharmaceuticals Reports Promising Phase 3 Results for Fibromyalgia Treatment
Tonix Pharmaceuticals Holding Corp. has unveiled positive Phase 3 trial data for TNX-102 SL, a potential breakthrough in fibromyalgia treatment, showcasing significant pain reduction and improved sleep quality, marking a significant advancement in pain management therapies.